

RESEARCH ARTICLE



Cite this: *RSC Med. Chem.*, 2024, 15, 1652

Chiral hydroxymethyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles: the search for selective p53-activating agents for colorectal cancer therapy†

Mees M. Hendriks,^a Adelino M. R. Pereira,^a Ana B. Pereira,^a Carla S. C. Carvalho,^b João L. P. Ribeiro,^a Maria I. L. Soares,^a Lucília Saraiva^{*b} and Teresa M. V. D. Pinho e Melo^{*a}

MANIO is an efficient p53-activating anticancer agent with remarkable selectivity to the p53 pathway and promising antitumor activity against colorectal cancer (CRC). Herein, a library of novel MANIO derivatives, including hydroxymethyl- and bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles, was synthesized by rational structural modulation. The antiproliferative activity of twenty derivatives was evaluated in a panel of human CRC cells with different p53 status. From this library, five compounds with *R*- and *S*-configuration and with aromatic or heteroaromatic groups at position 3, including the enantiomer of MANIO, were identified as selective towards p53-expressing cancer cells. On the other hand, two compounds with *S*-configuration, 6-hydroxymethyl- and 7-hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles, showed high cytotoxicity against WTp53-expressing HCT116 colon cells but, unlike MANIO, exhibited p53-independent inhibitory activity in CRC. The results described provide relevant structural and pharmacophoric data for the design of new p53-activating agents for precision therapy of CRC or other p53-related cancers harboring both wild-type or mutated p53 forms.

Received 26th January 2024,
Accepted 1st April 2024

DOI: 10.1039/d4md00076e


rsc.li/medchem

Introduction

Cancer is currently a major public health concern, with both incidence and mortality rates expected to increase in the coming decades.^{1,2} Among the various types of cancer, colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related deaths.^{3,4} The high mortality rates, often associated with treatment resistance and metastasization, highlight the limited effectiveness of existing therapies in treating CRC.⁴ Progress in understanding the development of CRC has revealed that p53 dysfunction is a key event in both localized and advanced cases of CRC. Impairment of the p53 pathway, either by TP53 mutation or inhibition of p53 by its negative regulators, is a significant event in both localized and advanced CRC. Thus, restoration of p53 activity has emerged as one of the most attractive anticancer therapeutic strategies.

Recently, our research team disclosed a new p53-activating anticancer drug, (3*S*)-6,7-bis(hydroxymethyl)-5-methyl-3-

phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (MANIO) (Fig. 1).⁵ MANIO represents a privileged anticancer drug compared to other currently available p53-activating agents regarding its antitumor activity in several cancer types, including CRC. MANIO showed a remarkable selectivity to the p53 pathway, activating wild-type (WT)p53 and restoring WT-like function to mutant (mut)p53 in human cancer cells. The half maximal inhibitory concentration (IC₅₀) value of MANIO in WTp53-expressing HCT116 colon cells, HCT116 p53^{+/+} (0.97 μM), was approximately 50-fold lower than that obtained in HCT116 p53^{-/-} cells (48.25 μM), indicating a significant p53-dependent growth inhibitory effect. MANIO has been shown to directly interact with the p53 DNA-binding domain (DBD), leading to activation of the p53 pathway. In fact, MANIO works as a bridging molecule between p53 and DNA. Ramos *et al.* have demonstrated that MANIO binds to



IC₅₀ = 0.97 μM (HCT116 p53^{+/+})
IC₅₀ = 48.25 μM (HCT116 p53^{-/-})

- *in vitro* and *in vivo* p53-dependent antitumor activity
- activation of WTp53 and restoration of WT-like function of mutp53
- synergism with conventional chemotherapeutics
- drug likeness and suitable PK profile

Fig. 1 Chemical structure and key features of (3*S*)-6,7-bis(hydroxymethyl)-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (MANIO) (1).

^a University of Coimbra, Coimbra Chemistry Centre – Institute of Molecular Sciences and Department of Chemistry, 3004-535 Coimbra, Portugal.

E-mail: tmelo@ci.uc.pt

^b LAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4md00076e>

a pocket formed between one dimer of the WTP53 DBD protein and the minor groove of the DNA molecule.⁵ MANIO interacts with the WTP53 DBD protein backbone through hydrogen bonds between its hydroxyl groups and the amide backbone groups of methionine 243 of chain A (M243A) and methionine 243 of chain B (M243B) (each belong to a different monomer). The remaining interactions of MANIO are stacking interactions made with the bases of DNA (DG8, DG12). In the specific case of mutp53 R248W, a highly frequent p53 mutation, in most clusters, the ligand makes a hydrogen bond between one of its hydroxyl oxygen atoms and the W248 side-chain nitrogen. The ligand phenyl group is close to the DNA bases adenine 6 and thymine 7. These interactions may eventually compensate for the loss of direct contacts between lysine 248 residue and the DNA. The latter interaction results in increased p53 stability, enhanced DNA-binding capacity and increased transcriptional activity. MANIO synergizes with conventional chemotherapeutics (e.g., doxorubicin (DOXO), cisplatin (CISP) and 5-fluorouracil (5-FU)) in patient-derived and immortalized CRC cells expressing WTP53 or mutp53. In addition, MANIO demonstrated *in vivo* p53-dependent anti-tumor activity in xenograft mouse models of CRC with no adverse side effects. It also demonstrated favorable drug-likeness and pharmacokinetic (PK) properties for a clinical candidate.⁵

In this study, structural modulation of MANIO, a lead p53-activating anticancer molecule, was performed with two main goals: to synthesize new bioactive 1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles and to gain in-depth knowledge of structure–activity relationships (SAR).

Results and discussion


Synthesis of new MANIO-like derivatives

The structural modulation strategy focused on structural changes of MANIO at position 3 of the 1*H*,3*H*-pyrrolo[1,2-*c*]thiazole core, namely the introduction of new aromatic, heteroaromatic, and alkyl substituents and the modification of the absolute configuration. These changes included the introduction of *p*-fluorophenyl, *p*-(trifluoromethoxy)phenyl, *p*-methoxyphenyl, bulky naphthyl and quinolinyl groups, and alkyl groups such as benzyl and methyl. Modifications in


other positions of the bicyclic system involved the removal of one hydroxymethyl group or the oxidation of the sulphur atom.

Chiral 1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles with *R*-configuration **3** were synthesized in moderate yields (35–69%) according to a known synthetic procedure (Scheme 1).⁶ Thiazolidines **2** were obtained from the reaction of *L*-cysteine with the corresponding aromatic aldehydes as mixtures of 2*R*,4*R*- and 2*S*,4*R*-diastereoisomers. The synthetic sequence proceeds *via* 1,3-dipolar cycloaddition of dimethyl acetylenedicarboxylate (DMAD) with the bicyclic münchnone generated *in situ* from thiazolidine **2**, followed by elimination of carbon dioxide. The acylation of the diastereoisomeric mixtures of thiazolidines with acetic anhydride or acyl chlorides can lead to the selective synthesis of *N*-acetyl-thiazolidine-4-carboxylic acids as pure stereoisomers with 2*S*,4*R*- or 2*R*,4*R*-configuration, depending on the reaction conditions.^{7–9} Thiazolidine **2** was heated in a solution of acetic anhydride in the presence of the dipolarophile. Under these reaction conditions the *N*-acylation occurs *in situ* giving selectively *N*-acetyl thiazolidine-4-carboxylic acids with 2*R*,4*R*-configuration. Thus, starting from thiazolidine-4-carboxylic acids **2** as a mixture of 2*R*,4*R*- and 2*S*,4*R*-diastereoisomers, chiral 1*H*-pyrrolo[1,2-*c*]thiazoles **3** were obtained as single enantiomer with *R*-configuration. In this process the chirality at C-4 of the thiazolidine is lost and the chirality at C-2 (C-3 in the product) is retained. The reduction of **3** was carried out with lithium aluminium hydride to afford the target 6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles **4** in moderate to good yields (34–75% for alcohols **4a**, **4d** and **4e**). The formation of alcohols **4b** and **4c** bearing an OCF₃ or CF₃ group in the *para* position of the phenyl group was confirmed by proton NMR spectroscopy. However, we decided not to proceed with the biological evaluation studies due to the lack of stability of these compounds.

Chiral 6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole **7** with *S*-configuration was also synthesized (Scheme 2). In order to obtain *N*-acetyl-thiazolidine-4-carboxylic acid with (2*S*,4*R*) stereochemistry we used an experimental procedure previously described in the literature.¹⁰ The reaction of thiazolidine **2f** with acetyl chloride in dry pyridine carried out at 0 °C allowed the selective formation of (2*S*,4*R*)-*N*-acetyl-thiazolidine-4-carboxylic acid **5**. Reaction of **5** with DMAD



Scheme 1 Synthesis of chiral 6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles **4**.



Scheme 2 Synthesis of (3*S*)-6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole **7**.


afforded the 1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6,7-dicarboxylate **6** with *S*-configuration in 69% yield. Further reduction with lithium aluminium hydride afforded 6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole **7** in good yield (74%).

(3*S*)-7-Hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**11**) and (3*S*)-6-hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**12**), which differ in the position of the hydroxymethyl group, were also synthesized (Scheme 3). Chiral 1*H*,3*H*-pyrrolo[1,2-*c*]thiazole carboxylates **9** and **10** were synthesized in moderate yield (67%) as a regioisomeric mixture (1:1) following a known synthetic procedure.⁶ Diastereoisomerically pure (2*S*,4*R*)-*N*-acetylthiazolidine-4-carboxylic acid **8**¹⁰ was used to generate the corresponding bicyclic münchnone *in situ*, which reacted with methyl propiolate *via* 1,3-dipolar cycloaddition. The


mixture of products could not be separated by chromatography. However, 1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6-carboxylate **10** was isolated in pure form by selective crystallization from diethyl ether/hexane. The structural assignment of compound **10**, made by comparison with the characterization data of the corresponding *R*-enantiomer,¹¹ which differed only in the optical rotation, allowed us to conclude that we were in the presence of a 1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6-carboxylate with *S*-configuration.

The reduction of (3*S*)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6-carboxylate **10** was carried out with lithium aluminium hydride to afford the corresponding alcohol **12** in 55% yield. A mixture of the regioisomeric alcohols 7-hydroxymethyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole **11** and 6-hydroxymethyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole **12** was obtained by reduction of the crude mixture of the corresponding carboxylate derivatives **9** and **10** with lithium aluminium hydride. Compounds **11** and **12** were successfully separated by column chromatography. This two-step synthetic approach afforded alcohols **11** and **12** in 10.5% and 16% overall yields, respectively.

The sulfone functional group is known to impart polarity to molecules, reducing their lipophilicity and improving their solubility in aqueous media, and the cyclic sulfone nucleus in particular is commonly found in biologically active compounds.¹² Thus, the sulfone of the enantiomer of MANIO was prepared starting from dimethyl (3*R*)-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6,7-dicarboxylate (**13**), whose synthesis was previously described by our group.¹³ In this case, the reduction was carried out with a sodium borohydride-methanol system instead of LiAlH₄, as the latter was found to reduce both the ester and the sulfone groups. The reaction of sulfone **13** with the NaBH₄-methanol system in refluxing THF for 24 h allowed the synthesis of the target sulfone **15** in 52% yield, which was obtained together with the mono-reduced derivative, compound **14**, in 31% yield (Scheme 4). Attempts to favor the exclusive formation of



Scheme 3 Synthesis of hydroxymethyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles **11** and **12**. ^ayield over two steps.



Scheme 4 Reduction of dimethyl (3*R*)-5-methyl-2,2-dioxo-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6,7-dicarboxylate (**13**).

compound **15**, by prolonging the reaction time, were unsuccessful.


6,7-Bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles **17** bearing methyl or benzyl groups at position 3 were also prepared from the corresponding 1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6,7-dicarboxylates **16**^{14,15} as outlined in Scheme 5. The target chiral molecules **17** were obtained in yields ranging from 57 to 75%.

Antiproliferative effect on CRC cells of MANIO-like derivatives

A small library of hydroxymethyl- and bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles and a bis(hydroxymethyl)-1*H*,3*H*-pyrazolo[1,5-*c*]thiazole were screened for p53-dependent anticancer activity. These included 1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles, the synthesis of which has been described above, as well as hydroxymethyl- and bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles **18** and 6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrazolo[1,5-*c*]thiazole **19** previously described by our research group (Fig. 2).^{10,11,16}

In vitro studies regarding the antiproliferative activity of compounds **18** and **19** have been carried out in a panel of human colorectal cancer cells with different p53 status, WTP53-expressing HCT116 colon cells (HCT116 p53^{+/+}) and p53 null isogenic derivative (HCT116 p53^{-/-}). The comparison of the activity of the compounds was made by analyzing the

corresponding IC₅₀ values (Table 1). 1*H*,3*H*-Pyrrolo[1,2-*c*]thiazole **18a**, the enantiomer of MANIO, was characterized by its high selectivity for HCT116 colon cells expressing p53 HCT116 p53^{+/+} with IC₅₀ = 5.11 μM, whereas the IC₅₀ value obtained for the p53 null isogenic derivative (HCT116 p53^{-/-}) was higher than 50 μM. Nevertheless, the IC₅₀ value for **18a** against HCT116 p53^{+/+} was 5-fold higher than that obtained for MANIO in the same cells. Compound **18b**, containing a hydroxymethyl group at C-6, and 6,7-bis(hydroxymethyl) derivative **18g**, containing a *p*-methoxyphenyl group at position 3, both with *R*-configuration, also showed a marked selectivity to p53-expressing cancer cells, with IC₅₀ values of 6.68 and 4.61 μM, respectively, compared to p53-null cells (>50 μM). Among the other compounds tested, none of them showed relevant selectivity for the WTP53-expressing HCT116 colon cells. Compound **18c**, which differs from **18b** only in the position of the hydroxymethyl group, shows a marked



Scheme 5 Synthesis of chiral 3-methyl- and 3-benzyl-6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles.




Fig. 2 Chemical structures of previously synthesized 1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles and 1*H*,3*H*-pyrazolo[1,5-*c*]thiazole.^{10,11,16}

Table 1 IC₅₀ values of compounds **18** and **19** in WTP53-expressing HCT116 colon cells (HCT116 p53^{+/+}) and p53-null isogenic derivative (HCT116 p53^{-/-})

Compound	IC ₅₀ (μM)	
	HCT116 p53 ^{+/+}	HCT116 p53 ^{-/-}
1 (MANIO)	0.97 ± 0.04	48.25 ± 1.97
18a (MANIO enantiomer)	5.11 ± 0.42	51.83 ± 2.73
18b	6.68 ± 1.22	>50
18c	29.34 ± 2.08	>50
18d	28.32 ± 3.51	>50
18e	20.30 ± 1.53	>50
18f	>50	>50
18g	4.61 ± 0.59	>50
18h	16.65 ± 2.31	>50
19	>50	>50

loss of selectivity for HCT116 colon cells expressing p53 HCT116 p53^{+/+}. A similar loss of selectivity was observed for compound **18d**, which differs from **18b** only in having no substituents at C-3. Compound **18e**, without substituents at the 5-position, showed a loss of selectivity of the same order of magnitude compared to compound **18a**. Although the introduction of a *p*-methoxyphenyl group at position 3 resulted in good performance, as observed for compound **18g**, the introduction of a bulkier trimethoxyphenyl group (compound **18f**) resulted in a complete loss of activity against HCT116 colon cells. On the other hand, compound **18h**, with a *p*-hydroxyphenyl group at C-3, showed lower selectivity and an IC₅₀ against HCT116 p53^{+/+} 3-fold higher than that observed for **18a**. Finally, compound **19** with a 1*H*,3*H*-pyrazolo[1,5-*c*]thiazole core showed no activity against HCT116 colon cells.

SAR data allowed the identification of potential pharmacophores in the molecule and the definition of new MANIO-like derivatives to be studied (Fig. 3). It has been shown that the presence of an aryl group at C-3, a methyl group at C-5 and the presence of an hydroxymethyl group at position 6 may be crucial to ensure good antiproliferative activity in HCT116 colon cells expressing WTP53. Thus, the design of new 1*H*,3*H*-pyrazolo[1,5-*c*]thiazoles involved the structural modulation at position 3 through the introduction of fluorine containing aromatic substituents, naphthyl or

quinolinyl groups. Among the new synthesized compounds, enantiomers of the most promising compounds studied (compounds **18b** and **18g**) were also prepared, as well as the sulfone of the enantiomer of MANIO. To confirm the importance of an aryl group at C-3 in ensuring good anticancer activity, the replacement of this type of functional group by alkyl groups was also carried out, resulting in novel 3-alkylated-6,7-bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole derivatives.

The antiproliferative activity of the newly synthesized 1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles **4**, **7**, **11**, **12**, **15** and **17** as well as compound **20**, whose synthesis was previously reported by our group,¹⁰ was evaluated in a panel of human colorectal cancer cells with different p53 status (Fig. 4, Table 2). (3*R*)-6,7-Bis(hydroxymethyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole **4a** with a *p*-fluorophenyl substituent at position 3 showed good selectivity for HCT116 p53^{+/+} with an IC₅₀ of 4.43 μM in contrast to the IC₅₀ of 32.50 μM against HCT116 p53^{-/-} cells. Compound **4e**, containing a quinolinyl group at C-3, had a slightly higher IC₅₀ value in the HCT116 p53^{+/+} cells (7.50 μM) than **4a**, however it showed higher selectivity for the p53 pathway, with the IC₅₀ value obtained in HCT116 p53^{-/-} cells higher than 50 μM. Compound **15**, the sulfone of the enantiomer of MANIO, showed higher IC₅₀ values than MANIO enantiomer (compound **18a**, Table 1), indicating that sulfur oxidation did not lead to an improvement of the anticancer activity. Compound **20**, which differs from MANIO only by the presence of two methyl groups at position 1, showed moderate anticancer activity in HCT116 p53^{+/+} cells (IC₅₀ = 24.34 μM) and no dependence on the p53 pathway (HCT116 p53^{-/-}; IC₅₀ = 22.15 μM).

3-Alkyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazoles **17** showed moderate p53 dependence, with IC₅₀ values in HCT116 p53^{+/+} (16–33 μM) only about 10 μM lower than those in p53 null isogenic cells (29–46 μM). As mentioned above, MANIO interacts with the WTP53 DBD protein backbone through hydrogen bonds between its hydroxyl groups and the amide backbone groups of the methionine residues of two different monomers, and through stacking interactions made with the bases of the DNA.⁵ This is in agreement with the results obtained for the alkylated derivatives, in particular for compounds **17b** and




Fig. 3 Structural modulation approaches based on SAR data.




Fig. 4 Chemical structures of new chiral hydroxymethyl- and bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles.

Table 2 IC₅₀ values of compounds 4a, 4d, 4e, 7, 11, 12, 15, 17 and 20 in WTP53-expressing HCT116 colon cells (HCT116 p53^{+/+}) and p53-null isogenic derivative (HCT116 p53^{-/-})

Compound	IC ₅₀ (μM)	
	HCT116 p53 ^{+/+}	HCT116 p53 ^{-/-}
4a	4.43 ± 2.13	32.50 ± 1.30
4d	ND	ND
4e	7.50 ± 1.10	>50
7	1.47 ± 0.66	23.50 ± 2.50
11	0.14 ± 0.07	18.11 ± 1.62
12	0.99 ± 0.05	4.33 ± 1.10
15	>15	>50
17a	16.27 ± 1.15	29.11 ± 1.00
17b	33.28 ± 1.73	46.19 ± 2.31
17c	31.40 ± 3.51	42.73 ± 3.61
20	24.34 ± 2.86	22.15 ± 4.17

ND: not determined due to insolubility in the medium used to grow the cells.

17c, where these aromatic stacking interactions are not possible.

The IC₅₀ value of compound 7 in HCT116 p53^{+/+} (1.47 μM) was 3-fold lower than that obtained for its enantiomer, compound 18g (see Table 1). However, in contrast to its enantiomer, it showed lower selectivity for HCT116 p53^{-/-} cells (IC₅₀ = 23.50 μM).

Mono-hydroxymethyl derivatives, regioisomers 11 and 12, showed excellent activity for HCT116 p53^{+/+} cells, with IC₅₀ values of 0.11 and 0.99 μM, respectively. Remarkably, the IC₅₀ value of 11 is about 200-fold lower than that obtained for its enantiomer (compound 18c, Table 1) but 7-fold lower than that obtained for MANIO. However, compounds 11 and 12 showed a low p53-dependent anti-proliferative effect with

IC₅₀ values of 18.11 and 4.33 μM for HCT116 p53^{-/-} cells, respectively.

Antiproliferative effect on MDA-MB-231, PANC-1 and A375 cells of MANIO-like derivatives

The antiproliferative activity of the most active compounds against HCT116 colon cells (HCT116 p53^{+/+}) was then evaluated in a panel of different human cancer cell lines, triple-negative breast cancer (MDA-MB-231), pancreatic adenocarcinoma (PANC-1) and melanoma (A375) (Table 3). However, none of the compounds showed relevant activity in any of the cell lines tested. Of note is the moderate activity of MANIO, its enantiomer and compound 12 in the human melanoma cell line (IC₅₀ < 15 μM).

Conclusion

Structural modulation of the lead compound MANIO was performed resulting in the synthesis of thirteen new 1H,3H-pyrrolo[1,2-c]thiazoles with R and S configuration. The antiproliferative activity of a library of twenty compounds was assessed in a panel of human colorectal cancer cells with different p53 status, providing relevant structural and pharmacophoric information.

Among the compounds tested, five, including the enantiomer of MANIO, all with aromatic or heteroaromatic substituents at C-3, showed selectivity towards p53-expressing cancer cells, with IC₅₀ values in cancer cells expressing WTP53 (HCT116 p53^{+/+}) ranging between 1.47 and 7.50 μM and IC₅₀ > 23.50 μM in p53-null isogenic derivatives (HCT116 p53^{-/-}). It was observed that the *p*-methoxyphenyl-substituted derivative with *S*-configuration showed significantly higher activity against HCT116 p53^{+/+} cells than its enantiomer, 1.47 vs. 4.61 μM.

Mono-hydroxymethyl derivatives with *S*-configuration stood out for their high antiproliferative activity in colon cancer cells expressing WTP53, with IC₅₀ < 1 μM, higher activity than the corresponding enantiomers and MANIO, but no p53-dependent growth-inhibitory effect.

Collectively, these results indicate that the presence of aromatic substituents at C-3 and a methyl group at C-5 are essential to ensure effective p53-dependent growth inhibitory activity. Furthermore, the absolute configuration at the chiral center was shown to play an important role in the antiproliferative activity in WTP53-expressing colon cancer cells. It was also observed that the position of the hydroxymethyl group in mono-hydroxymethyl derivatives affects also the inhibitory activity. Interestingly, while for 1H,3H-pyrrolo[1,2-c]thiazoles with *R* configuration the 6-hydroxymethyl derivative was significantly more active than the 7-hydroxymethyl derivative, in the case of 1H,3H-pyrrolo[1,2-c]thiazoles with *S* configuration, both 6-hydroxymethyl and 7-hydroxymethyl derivative show outstanding antiproliferative activity in WTP53-expressing HCT116 colon cells, but p53-independent inhibitory activity.

Table 3 IC₅₀ values of most active compounds in HCT116 p53^{+/+} cells in PANC-1, A375 and MDA-MB-231 cell lines

Compound	IC ₅₀ ^a (μM)		
	MDA-MB-231	PANC-1	A375
1 (MANIO)	>50	42.15 ± 2.32	13.20 ± 0.71
18a (MANIO enantiomer)	>50	33.10 ± 1.27	14.49 ± 1.85
18b	>50	>50	39.50 ± 1.41
18g	>50	>50	>50
4a	>50	20.15 ± 2.76	36.14 ± 1.32
4e	>50	17.35 ± 2.48	24.35 ± 2.62
7	16.57 ± 1.86	>50	22.80 ± 0.91
12	24.11 ± 2.09	35.00 ± 2.57	11.78 ± 1.84
11	>50	>50	>50

^a Values correspond to the media ± standard deviation of 3 independent experiments.

Overall, the present work represents a successful strategy of modulation and rational structural optimization of a lead molecule, which allowed to gather pertinent structural and pharmacophoric data for the design of new p53-activating agents for precision therapy of CRC or other cancers harboring WT or mutp53.

Experimental

Chemistry

Thin-layer chromatography (TLC) analyses were performed using precoated silica gel plates. Column chromatography was performed with silica gel 60 as the stationary phase. ¹H Nuclear magnetic resonance (NMR) spectra (400 MHz), ¹³C NMR spectra (100 MHz) and ¹⁹F spectra (376 MHz) were recorded in CDCl₃, CD₃OD or hexadeuterated dimethylsulfoxide (DMSO-*d*₆). Chemical shifts are expressed in parts per million (ppm) relatively to internal tetramethylsilane (TMS), and coupling constants (*J*) are in hertz. Infrared (IR) spectra were recorded in a Fourier transform spectrometer using either a KBr matrix or diamond attenuated total reflectance (ATR) mode. Elemental analyses were carried out with an Elemental Vario Micro Cube analyser. High-resolution mass spectra (HRMS) were obtained on a TOF VG Autospect M spectrometer with electron impact (EI), on a Thermo Orbitrap Q-Exactive Focus spectrometer with electrospray ionization (ESI) or on a Bruker MicroTOF (APCI-FIA-TOF). Melting points were determined in open glass capillaries and are uncorrected. Optical rotations were measured on an Optical Activity AA-5 electrical polarimeter.

Thiazolidine-4-carboxylic acids **2a**,⁸ **2c**,¹⁷ **2d**,¹⁸ **2f**,¹⁶ *N*-acetyl-thiazolidine **8**,¹⁰ *1H,3H*-pyrrolo[1,2-*c*]thiazoles **16**,^{14,15} hydroxymethyl- and bis(hydroxymethyl)-*1H,3H*-pyrrolo[1,2-*c*]thiazoles **18**,^{10,11,16} bis(hydroxymethyl)-*1H,3H*-pyrazolo[1,5-*c*]thiazole **19**,¹⁰ and *1H,3H*-pyrrolo[1,2-*c*]thiazole-2,2-dioxide **13**¹³ were prepared as described in the literature.

General procedure for the synthesis of 1,3-thiazolidine-4-carboxylic acids 2. A solution of the corresponding aldehyde (29.0 mmol) in ethanol (22 mL) was added to a solution of

L-cysteine (3.51 g, 29.0 mmol) in water (22 mL). The reaction was stirred for 5 h, the product was filtered and washed with diethyl ether.

2-(4-(Trifluoromethoxy)phenyl)-1,3-thiazolidine-4-carboxylic acid (2b). Obtained from 4-(trifluoromethoxy)benzaldehyde (5.51 g, 29.0 mmol) as described in the general procedure. Yield: 75% (6.39 g), white solid, mp 146.6–147.6 °C. The ¹H NMR spectrum obtained at 25 °C showed the presence of the two diastereoisomers (*2R,4R*) and (*2S,4R*) (ratio 40:60); ¹H NMR (400 MHz, DMSO-*d*₆): δ = 3.08–3.14 (2 × m, 2H), 3.32 and 3.38 (2 × dd, *J* = 10.2, 7.0 Hz and *J* = 10.0, 7.0 Hz, 2H), 3.92 and 4.18 (2 × dd, *J* = 8.8, 7.0 Hz and *J* = 6.8, 5.1 Hz, 2H), 5.56 and 5.74 (2 × s, 2H), 7.32 and 7.36 (2 × d, *J* = 8.1 Hz and *J* = 8.1 Hz, ArH, 4H), 7.56–7.58 and 7.66–7.68 (2 × m, ArH, 4H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 38.0 and 38.3, 64.8 and 65.6, 69.9 and 70.6, 120.0 (q, ¹*J*_{C-F} = 254 Hz), 120.7 and 120.9, 128.8 and 129.4, 138.6 and 141.2, 147.5 and 148.0, 172.0 and 172.8. ¹⁹F NMR (376 MHz, DMSO-*d*₆): δ = -56.79 and -56.78. IR (ATR): ν = 1572, 1509, 1437, 1381, 1251, 1208, 1163 cm⁻¹. HRMS (ESI): calcd for C₁₁H₁₁NO₃F₃S [M + H]⁺ 294.0406; found 294.0401.

2-(Quinolin-8-yl)thiazolidine-4-carboxylic acid (2e). Obtained from quinoline-8-carbaldehyde (2.50 g, 15.9 mmol) as described in the general procedure. Yield: 95% (3.96 g), white solid, mp 129.8–131.1 °C. The ¹H NMR spectrum obtained at 25 °C showed the presence of the two diastereoisomers (*2R,4R*) and (*2S,4R*) (ratio 50:50); ¹H NMR (400 MHz, CD₃-OD): δ = 3.44–3.49 (2 × m, 2H), 3.59–3.68 (2 × m, 2H), 4.32 and 4.57 (2 × pseudo-t, *J* = 7.6 Hz and *J* = 6.5 Hz, 2H), 6.52 and 6.72 (2 × s, 2H), 7.58–7.66 (m, ArH, 4H), 7.95–8.02 (m, ArH, 4H), 8.39–8.42 (m, ArH, 2H), 8.96–8.98 (m, ArH, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 37.3, 38.4, 65.3, 65.8, 66.2, 67.9, 121.4, 121.6, 124.6, 126.2, 126.3, 127.1, 127.4, 127.9, 130.0, 128.2, 136.3, 136.7, 140.2, 144.9, 145.2, 149.2, 149.6, 172.4, 172.9. IR (ATR): ν = 1606, 547, 1500, 1397, 1359, 1314 cm⁻¹. HRMS (ESI): calcd for C₁₃H₁₃N₂O₂S [M + H]⁺ 261.0692; found 261.0688.

(2S,4R)-3-Acetyl-2-(4-methoxyphenyl)thiazolidine-4-carboxylic acid (5). The compound was prepared according to a procedure described in the literature for the synthesis of (*2S,4R*)-3-acetyl-2-phenylthiazolidine-4-carboxylic acid.¹⁰

Yield: 61%, white solid, mp 148.4–149.9 °C (from ethanol). The ^1H NMR spectrum obtained at 25 °C showed the presence of the two rotational isomers; ^1H NMR (400 MHz, CD_3OD): δ = 1.76 and 2.01 (2 \times s, 3H), 3.15–3.47 (2 \times m, 2H), 3.73 and 3.76 (2 \times s, 3H), 5.10 and 5.32 (2 \times d, J = 6.9 Hz and J = 6.0 Hz, 1H), 6.12 and 6.33 (2 \times s, 1H), 6.83 and 6.92 (d, J = 8.7 Hz, 2H), 7.19 and 7.24 (d, J = 8.7 Hz, 2H). IR (ATR): ν = 1706, 1597, 1513, 1403, 1243, 1182, 1030 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{13}\text{H}_{16}\text{NO}_4\text{S}$ [$\text{M} + \text{H}$] $^+$ 282.0795; found 282.0792. [α_{D}^{20} = -270 (c 0.5, DCM).

General procedure for the synthesis of 1H,3H-pyrrolo[1,2-c]thiazole carboxylates. A solution of the appropriate thiazolidine-4-carboxylic acid (18.0 mmol), dipolarophile (1.5 or 1.8 equiv.) and Ac_2O (60 mL) was heated at 110 °C for the time indicated. The reaction was cooled to room temperature and was diluted with CH_2Cl_2 (150 mL). The organic phase was washed with saturated aqueous solution of NaHCO_3 and with water, dried (Na_2SO_4) and the solvent evaporated off. The crude product was purified by column chromatography [hexane–ethyl acetate].

Dimethyl (3R)-3-(4-fluorophenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (3a). Obtained from thiazolidine **2a** (2.02 g, 8.8 mmol) and DMAD (1.88 g, 13.2 mmol, 1.5 equiv.) as described in the general procedure. Reaction time: 12 h. Purification by column chromatography [hexane/EtOAc (1:2), (1:1), then (2:1)] gave compound **3a** as solid (2.30 g, 69%). Recrystallization from EtOAc/hexane gave the compound as a pale-yellow solid, mp 101.8–102.3 °C. ^1H NMR (400 MHz, CDCl_3): δ = 2.00 (s, 3H), 3.83 (s, 1H), 3.83 (s, 1H), 4.32 (d, J = 15.0 Hz, 1H), 4.47 (dd, J = 15.0, 1.6 Hz, 1H), 6.28 (d, J = 1.6 Hz, 1H), 7.03–7.08 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3): δ = 11.4, 30.0, 51.4, 51.6, 64.4, 107.0, 116.3 (d, $^2 J_{\text{C-F}}$ = 22.9 Hz), 117.6, 127.6 (d, $^3 J_{\text{C-F}}$ = 8.4 Hz), 130.5, 136.0 (d, $^4 J_{\text{C-F}}$ = 3.2 Hz), 140.3, 162.8 (d, $^1 J_{\text{C-F}}$ = 247 Hz), 164.0, 165.2. ^{19}F NMR (376 MHz, CDCl_3): δ = -114.47. IR (ATR): ν = 2952, 1773, 1699, 1508, 1436, 1291, 1219, 1150, 1090 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{17}\text{NO}_4\text{FS}$ [$\text{M} + \text{H}$] $^+$ 350.0857; found 350.0853. [α_{D}^{20} = +185 (c 1, CH_2Cl_2).

Dimethyl (3R)-5-methyl-3-(4-(trifluoromethoxy)phenyl)-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (3b). Obtained from thiazolidine **2b** (2.00 g, 6.8 mmol) and DMAD (1.45 g, 10.2 mmol, 1.5 equiv.) as described in the general procedure. Reaction time: 12 h. Purification by column chromatography [hexane/EtOAc (1:1)] gave compound **3b** as a colorless oil (1.85 g, 65%). ^1H NMR (400 MHz, CDCl_3): δ = 2.02 (s, 3H), 3.83 (s, 6H), 4.33 (d, J = 15.0 Hz, 1H), 4.47 (dd, J = 15.0, 1.6 Hz, 1H), 6.29 (d, J = 1.5 Hz, 1H), 7.06–7.12 (m, 2H), 7.20 (d, J = 8.2 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ = 11.5, 30.0, 51.5, 51.6, 64.1, 107.1, 116.5, 120.3 (d, $^1 J_{\text{C-F}}$ = 256 Hz), 121.7, 127.2, 130.5, 138.9, 140.3, 149.4 (d, $^3 J_{\text{C-F}}$ = 1.5 Hz), 163.9, 165.2. ^{19}F NMR (376 MHz, CDCl_3): δ = -57.88. IR (ATR): ν = 2952, 1702, 1509, 1439, 1252, 1208, 1155, 1092 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{17}\text{NO}_5\text{F}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 416.0774; found 416.0770. [α_{D}^{20} = +107 (c 0.5, CH_2Cl_2).

Dimethyl (3R)-5-methyl-3-(4-(trifluoromethyl)phenyl)-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (3c). Obtained from

thiazolidine **2c** (2.00 g, 7.2 mmol) and DMAD (1.54 g, 10.8 mmol, 1.5 equiv.) as described in the general procedure. Reaction time: 4 h. Purification by column chromatography [hexane/EtOAc (3:1)] gave compound **3c** as an oil (1.44 g, 50%). Recrystallization from EtOAc/hexane gave the compound as white solid, mp 105.6–106.6 °C. ^1H NMR (400 MHz, CDCl_3): δ = 2.03 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 4.34 (d, J = 14.9 Hz, 1H), 4.47 (dd, J = 1.5 and 14.9, 1H), 6.32 (d, J = 1.2 Hz, 1H), 7.16 (d, J = 8.1 Hz, 2H), 7.62 (d, J = 8.2 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ = 11.5, 30.1, 51.5, 51.6, 64.1, 107.3, 117.8, 123.7 (q, $^1 J_{\text{C-F}}$ = 272 Hz), 125.9, 126.4 (q, $^3 J_{\text{C-F}}$ = 3.7 Hz), 130.4, 131.2 (q, $^2 J_{\text{C-F}}$ = 32.7 Hz), 140.3, 144.2, 163.9, 165.1. ^{19}F NMR (376 MHz, CDCl_3): δ = -62.79. IR (ATR): ν = 2950, 1705, 1437, 1323, 1204, 1126, 1090, 1065 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{17}\text{NO}_4\text{F}_3\text{S}$ [$\text{M} + \text{H}$] $^+$ 400.0825; found 400.0822. [α_{D}^{20} = +180 (c 0.5, CH_2Cl_2).

Dimethyl (3R)-5-methyl-3-(naphthalen-1-yl)-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (3d). Obtained from thiazolidine **2d** (2.00 g, 7.7 mmol) and DMAD (1.64 g, 11.6 mmol, 1.5 equiv.) as described in the general procedure. Reaction time: 4 h. Purification by column chromatography [hexane/EtOAc (3:1), then hexane/EtOAc (2:1)] gave compound **3d** as a solid (1.03 g, 35%). Recrystallization from EtOAc/hexane gave the compound as pale-yellow solid, mp 192.9–194.8 °C. ^1H NMR (400 MHz, CDCl_3): δ = 2.08 (s, 3H), 3.85 (s, 6H), 4.36 (s, 2H), 6.51 (bs, 1H), 6.98 (s, 1H), 7.34 (pseudo-t, J = 7.7 Hz, 1H), 7.55–7.62 (m, 2H), 7.82 (d, J = 8.3 Hz, 1H), 7.88–7.93 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ = 11.5, 29.8, 51.4, 51.6, 61.1, 107.5, 117.2, 121.0, 122.1, 125.5, 126.4, 127.1, 129.3, 129.3, 131.1, 134.0, 135.4, 141.1, 164.0, 165.3. IR (ATR): ν = 2947, 1726, 1698, 1534, 1433, 1204, 1154, 1093 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{21}\text{H}_{20}\text{NO}_4\text{S}$ [$\text{M} + \text{H}$] $^+$ 382.1108; found 382.1103. [α_{D}^{20} = +396 (c 0.5, CH_2Cl_2).

Dimethyl (3R)-5-methyl-3-(quinolin-8-yl)-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (3e). Obtained from thiazolidine **2e** (2.01 g, 7.7 mmol) and DMAD (1.64 g, 11.6 mmol, 1.5 equiv.) as described in the general procedure. Reaction time: 4 h. Purification by column chromatography [hexane/EtOAc (1:1)] gave compound **3e** as a solid (1.35 g, 46%). Recrystallization from EtOAc/hexane gave the compound as white solid, mp 203.9–205.8 °C (with decomposition). ^1H NMR (400 MHz, CDCl_3): δ = 2.10 (s, 3H), 3.85 (s, 3H), 3.86 (s, 3H), 4.31 (d, J = 15.1 Hz, 1H), 4.36 (dd, J = 0.8 and 15.1 Hz, 1H), 6.79 (d, J = 7.0 Hz, 1H), 7.43 (pseudo-t, J = 7.7 Hz, 1H), 7.50 (dd, J = 4.2 and 8.3 Hz, 1H), 7.54 (br s, 1H), 7.80 (dd, J = 1.1 and 8.2 Hz, 1H), 8.20 (dd, J = 1.7 and 8.3 Hz, 1H), 8.97 (dd, J = 1.7 and 4.2 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ = 11.5, 29.5, 51.4, 51.6, 60.1, 107.3, 117.0, 121.8, 123.8, 126.4, 128.5, 131.0, 136.3, 138.2, 141.5, 144.5, 150.0, 164.1, 165.4. IR (ATR): ν = 2946, 1725, 1696, 1534, 1444, 1385, 1303, 1204, 1156, 1092 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_4\text{S}$ [$\text{M} + \text{H}$] $^+$ 383.1060; found 383.1057. [α_{D}^{20} = +434 (c 0.5, CH_2Cl_2).

Dimethyl (3S)-3-(4-methoxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (6). Obtained from *N*-acetyl-thiazolidine **5** (0.81 g, 2.9 mmol) and DMAD (0.61 g,

4.3 mmol, 1.5 equiv.) as described in the general procedure. Reaction time: 12 h. Purification by column chromatography [hexane/EtOAc (1:1)] gave compound **6** as a solid (0.72 g, 69%). Recrystallization from EtOAc/hexane gave the compound as pale-yellow solid, mp 86.3–88.1 °C. ^1H NMR (400 MHz, CDCl_3): δ = 2.00 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H), 4.30 (d, J = 14.9 Hz, 1H), 4.47 (dd, J = 1.7 and 14.9, 1H), 6.27 (d, J = 1.5 Hz, 1H), 6.85–6.87 (m, 2H), 7.01–7.03 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ = 11.4, 30.0, 51.4, 51.6, 55.4, 64.8, 106.7, 114.6, 117.4, 127.2, 130.8, 131.9, 140.4, 160.1, 164.1, 165.5. IR (ATR): ν = 2958, 1687, 1513, 1447, 1230, 1169, 1091, 1027 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{20}\text{NO}_5$ $[\text{M} + \text{H}]^+$ 362.1057; found 362.1053. $[\alpha]_{\text{D}}^{20}$ = –183 (c 0.5, CH_2Cl_2).

Methyl (3S)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxylate (9) and methyl (3S)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole-6-carboxylate (10). Obtained from *N*-acetyl-thiazolidine **8** (2.00 g, 7.96 mmol) and methyl propiolate (1.20 g, 14.33 mmol, 1.8 equiv.) as described in the general procedure. Reaction time: 16 h. Purification by column chromatography [hexane/EtOAc (2:1)] gave a mixture of **9** and **10** (50:50) (1.46 g, 67%). Compound **10** could be separated by selective crystallization with diethyl ether-hexane. *Methyl (3S)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole-6-carboxylate (10)*: pale-yellow solid, mp 89.7–91.7 °C. ^1H NMR (400 MHz, CDCl_3): δ = 2.18 (s, 3H), 3.78 (s, 3H), 4.02 (d, J = 13.1 Hz, 1H), 4.27 (d, J = 13.1 Hz, 1H), 6.25 (s, 1H), 6.33 (s, 1H), 7.01 (dd, J = 1.7 and 7.7 Hz, 2H), 7.29–7.35 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ = 11.8, 28.2, 50.8, 64.0, 101.7, 116.6, 125.4, 128.6, 129.1, 132.0, 133.2, 141.1, 165.8. IR (ATR): ν = 2923, 1688, 1523, 1363, 1222, 1169, 1068 cm^{-1} . HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2\text{S}$ $[\text{M} + \text{H}]^+$ 274.0896; found 274.0892. $[\alpha]_{\text{D}}^{20}$ = –320 (c 0.5, CH_2Cl_2). *Methyl (3S)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxylate (9)*: ^1H NMR (400 MHz, CDCl_3): δ = 1.82 (s, 3H), 3.81 (s, 3H), 4.34 (d, J = 14.7 Hz, 1H), 4.51 (dd, J = 1.8 and 14.7 Hz), 6.27 (d, J = 1.8 Hz, 1H), 6.36 (s, 1H), 7.06 (dd, J = 1.7 and 7.6 Hz, 2H), 7.30–7.35 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ = 12.1, 30.4, 51.0, 65.0, 106.9, 112.2, 125.7, 125.8, 128.8, 129.1, 140.3, 140.4, 165.2.

General procedure for the synthesis of hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles. A solution containing the appropriate 1H,3H-pyrrolo[1,2-c]thiazole (2.30 mmol) in dry dichloromethane (30 mL) was added dropwise to a suspension of lithium aluminium hydride (2.2 equiv., 192 mg, 5.06 mmol) in anhydrous diethyl ether at 0 °C, unless otherwise stated. After completing the addition, the reaction mixture was refluxed under nitrogen for 1.5 h and then cooled on an ice bath. The excess of hydride was carefully decomposed by addition of ethyl acetate followed by slow addition of water (0.2 mL), NaOH 15% (0.2 mL) and water (0.6 mL). The mixture was filtered through celite and the inorganic residue was washed with several portions of hot dichloromethane. The filtrate was dried (Na_2SO_4) and the solvent evaporated off. The crude product was purified by column chromatography [hexane–ethyl acetate] or recrystallisation and stored under nitrogen at –18 °C.

(3R)-6,7-Bis(hydroxymethyl)-3-(4-fluorophenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole (4a). Obtained from compound **3a** (1.06 g, 2.80 mmol) as described in the general procedure. Purification by column chromatography [hexane/EtOAc (1:2), then hexane/EtOAc (1:3)] followed by trituration with diethyl ether gave compound **4a** as a pale yellow solid (290 mg, 34%). mp \geq 85 °C, with decomposition. ^1H NMR (400 MHz, CDCl_3): δ = 1.83 (s, 3H), 2.99 (bs, 2H), 4.07 (d, J = 12.8 Hz, 1H), 4.27 (d, J = 12.8 Hz, 1H), 4.45 (d, J = 12.3 Hz, 1H), 4.49 (d, J = 12.3 Hz, 1H), 4.55 (s, 2H), 6.21 (d, J = 0.8 Hz, 1H), 6.97–7.06 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3): δ = 10.0, 27.6, 56.2, 56.5, 63.7, 113.5, 116.0 (d, $^2 J_{\text{C-F}}$ = 21.9 Hz), 122.9, 123.7, 127.6 (d, $^3 J_{\text{C-F}}$ = 8.4 Hz), 131.4, 137.5 (d, $^4 J_{\text{C-F}}$ = 3.1 Hz), 162.6 (d, $^1 J_{\text{C-F}}$ = 248 Hz). ^{19}F NMR (376 MHz, CDCl_3): δ = –113.04. IR (ATR): ν = 3326, 2863, 1604, 1508, 1354, 1226, 997 cm^{-1} . HRMS (APCI): calcd for $\text{C}_{15}\text{H}_{15}\text{FNOS}$ $[\text{M} - \text{OH}]^+$ 276.0853; found 276.0855. $[\alpha]_{\text{D}}^{20}$ = +221 (c 0.5, CH_2Cl_2).

(3R)-6,7-Bis(hydroxymethyl)-5-methyl-3-(4-(trifluoromethoxy)phenyl)-1H,3H-pyrrolo[1,2-c]thiazole (4b). Obtained from compound **3b** (1.72 g, 4.15 mmol) as described in the general procedure. Purification by column chromatography [hexane/EtOAc (1:2), then hexane/EtOAc (1:3)] gave compound **4b** (60 mg, 4%) in a very impure form.

(3R)-6,7-Bis(hydroxymethyl)-5-methyl-3-(4-(trifluoromethyl)phenyl)-1H,3H-pyrrolo[1,2-c]thiazole (4c). Obtained from compound **3c** (0.93 g, 2.34 mmol) as described in the general procedure. Purification by column chromatography [hexane/EtOAc (1:2), hexane/EtOAc (1:5), then EtOAc] gave compound **4c** in trace amount and in a very impure form.

(3R)-6,7-Bis(hydroxymethyl)-5-methyl-3-(naphthalen-1-yl)-1H,3H-pyrrolo[1,2-c]thiazole (4d). Obtained from compound **3d** (0.47 g, 1.15 mmol) as described in the general procedure. Purification by column chromatography [hexane/EtOAc (1:2), hexane/EtOAc (1:5), then EtOAc] gave compound **4d** as a white solid (255 mg, 53%). mp \geq 180 °C, with decomposition (trituration from diethyl ether). ^1H NMR (400 MHz, CDCl_3): δ = 1.92 (s, 3H), 2.68 (bs, 2H), 4.08 (d, J = 12.5 Hz, 1H), 4.22 (d, J = 12.8 Hz, 1H), 4.55 (d, J = 12.0 Hz, 1H), 4.60 (d, J = 12.2 Hz, 1H), 4.63 (s, 2H), 6.51 (bs, 1H), 6.91 (s, 1H), 7.33 (pseudo-t, J = 7.7 Hz, 1H), 7.53–7.60 (m, 2H), 7.79 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 7.9 Hz, 2H). IR (ATR): ν = 3297, 2869, 1541, 1431, 1353, 979, 777 cm^{-1} . HRMS (APCI): calcd for $\text{C}_{19}\text{H}_{18}\text{NOS}$ $[\text{M} - \text{OH}]^+$ 308.1104; found 308.1106. $[\alpha]_{\text{D}}^{20}$ = +540 (c 0.5, CH_2Cl_2).

(3R)-6,7-Bis(hydroxymethyl)-5-methyl-3-(quinolin-8-yl)-1H,3H-pyrrolo[1,2-c]thiazole (4e). Obtained from compound **3e** (1.24 g, 3.24 mmol) as described in the general procedure. Recrystallization of the crude product from EtOAc/hexane followed by trituration with diethyl ether gave the compound **4e** as a white solid (0.80 g, 75%). mp 148.3–150.1 °C. ^1H NMR (400 MHz, CDCl_3): δ = 1.95 (s, 3H), 2.52 (bs, 2H), 4.03 (d, J = 13.0 Hz, 1H), 4.20 (d, J = 13.0 Hz, 1H), 4.57 (d, J = 12.4 Hz, 1H), 4.61 (d, J = 12.4 Hz, 1H), 4.63 (d, J = 12.8 Hz, 1H), 4.66 (d, J = 12.8 Hz, 1H), 6.76 (d, J = 7.1 Hz, 1H), 7.39–7.43 (m, 1H), 7.44 (s, 1H), 7.48 (dd, J = 4.2 and 8.3, Hz, 1H), 7.76 (dd, J = 0.9 and 8.2 Hz, 1H), 8.18 (dd, J = 1.7 and 8.3 Hz, 1H),

8.98 (dd, $J = 1.7$ and 4.2 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 9.9, 27.1, 56.6, 56.9, 59.6, 113.8, 121.6, 123.0, 123.2, 124.0, 126.5, 128.0, 128.4, 132.3, 136.2, 139.6, 144.7, 149.8$. IR (ATR): $\nu = 3207, 2917, 2850, 1498, 1422, 1361, 984, 798\text{ cm}^{-1}$. HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M} - \text{H}]^+$ 327.1162; found 327.1156. $[\alpha]_{\text{D}}^{20} = +570$ (c 1, CH_2Cl_2).

(3*S*)-6,7-Bis(hydroxymethyl)-3-(4-methoxyphenyl)-5-methyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**7**). Obtained from compound **6** (0.51 g, 1.42 mmol) as described in the general procedure. Purification by trituration with diethyl ether yields compound **7** as a white solid (323 mg, 74%). mp 113–115 °C. ^1H NMR (400 MHz, CDCl_3): $\delta = 1.83$ (s, 3H), 2.43 (bs, 1H), 2.57 (bs, 1H), 3.79 (s, 3H), 4.07 (d, $J = 12.8$ Hz, 1H), 4.28 (d, $J = 12.8$ Hz, 1H), 4.48 (d, $J = 12.3$ Hz, 1H), 4.52 (d, $J = 12.2$ Hz, 1H), 4.58 (s, 2H), 6.21 (d, $J = 0.9$ Hz, 1H), 6.82–6.86 (m, 2H), 7.00–7.04 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 10.0, 27.6, 55.3, 56.4, 56.7, 64.2, 113.3, 114.3, 123.1, 123.5, 127.2, 131.5, 133.4, 159.7$. IR (ATR): $\nu = 3361, 2866, 1613, 1541, 1255, 1171, 1008, 819\text{ cm}^{-1}$. Anal. Calcd for $\text{C}_{16}\text{H}_{19}\text{NO}_3\text{S}$: C, 62.93; H, 6.27; N, 4.59; S, 10.50. Found: C, 62.80; H, 6.11; N, 4.44; S, 10.81. $[\alpha]_{\text{D}}^{20} = -280$ (c 0.5, CH_2Cl_2).

(3*S*)-7-Hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**11**) and (3*S*)-6-hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**12**). Obtained from the crude mixture of **9** and **10** [ratio (1:1)], from the reaction of *N*-acetyl-thiazolidine **8** (6.16 mmol) and methyl propiolate, as described previously] and LiAlH_4 (6.16 mmol), as described in the general procedure. In this case the reaction mixture was refluxed for 4 h after the addition was completed. Purification by column chromatography [hexane/EtOAc (2:1), then hexane/EtOAc (1:1)] gave in order of elution (3*S*)-7-hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**11**) (159 mg, 10.5%) and (3*S*)-6-hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**12**) (247 mg, 16%). (3*S*)-7-Hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**11**). White solid. mp 91–93 °C (trituration with diethyl ether). ^1H NMR (400 MHz, CDCl_3): $\delta = 1.36$ (bs, 1H), 1.83 (s, 3H), 4.09 (d, $J = 12.8$ Hz, 1H), 4.31 (d, $J = 12.8$ Hz, 1H), 4.52 (pseudo-t, $J = 12.2$ Hz, 2H), 5.98 (s, 1H), 6.22 (s, 1H), 6.90–7.14 (m, 2H), 7.28–7.35 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 12.1, 27.9, 58.3, 64.3, 111.3, 114.1, 125.1, 125.7, 128.4, 129.0, 131.8, 141.7$. IR (ATR): $\nu = 3376, 2907, 1438, 1377, 1344, 1004, 990, 708\text{ cm}^{-1}$. HRMS (ESI): calcd for $\text{C}_{14}\text{H}_{15}\text{NOSNa}$ $[\text{M} + \text{Na}]^+$ 268.0767; found 268.0761. $[\alpha]_{\text{D}}^{20} = -280$ (c 0.5, CH_2Cl_2). (3*S*)-6-Hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**12**). Pale pink solid. mp 61–63 °C (trituration with diethyl ether). ^1H NMR (400 MHz, CDCl_3): $\delta = 1.26$ (bs, 1H), 1.87 (s, 3H), 4.05 (d, $J = 12.8$ Hz, 1H), 4.30 (d, $J = 12.8$ Hz, 1H), 4.45 (s, 2H), 5.93 (s, 1H), 6.22 (d, $J = 1.4$ Hz, 1H), 7.03–7.05 (m, 2H), 7.28–7.32 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 10.0, 28.8, 58.2, 64.2, 100.1, 122.9, 124.9, 125.7, 128.4, 129.0, 133.0, 141.9$. IR (ATR): $\nu = 3363, 2899, 1337, 1110, 986, 695\text{ cm}^{-1}$. HRMS (APCI): calcd for $\text{C}_{14}\text{H}_{14}\text{NS}$ $[\text{M} - \text{OH}]^+$ 228.0841; found 228.0843. $[\alpha]_{\text{D}}^{20} = -300$ (c 0.5, CH_2Cl_2).

(3*S*)-6-Hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**12**). Obtained from compound **10** (0.45 g, 1.64

mmol) and LiAlH_4 (3.94 mmol) as described in the general procedure. In this case the reaction mixture was refluxed for 4 h after the addition was completed. Purification by column chromatography [hexane/EtOAc (1:1)] followed by trituration with diethyl ether yields compound **12** as a pale pink solid (221 mg, 55%). Compound **12** was identified by comparison with the specimen previously prepared (see above).

(3*R*)-6,7-Bis(hydroxymethyl)-3-benzyl-5-methyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**17a**). Obtained from compound **16a** (0.63 g, 1.83 mmol) as described in the general procedure. Purification by column chromatography [hexane/EtOAc (1:3), then hexane/EtOAc (1:5)] gave compound **17a** as a colorless oil (363 mg, 68%). ^1H NMR (400 MHz, CDCl_3): $\delta = 2.27$ (s, 3H), 2.62 (bs, 2H), 3.15–3.21 (m, 2H), 3.52 (d, $J = 12.9$ Hz, 1H), 3.65 (d, $J = 12.9$ Hz, 1H), 4.40 (s, 2H), 4.50 (d, $J = 12.6$ Hz, 1H), 4.54 (d, $J = 12.7$ Hz, 1H), 5.41 (t, $J = 4.9$ Hz, 1H), 7.03–7.05 (m, 2H), 7.23–7.25 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 10.1, 26.8, 44.5, 56.3, 56.5, 63.5, 113.2, 121.9, 123.2, 127.2, 128.2, 130.0, 131.5, 135.5$. IR (ATR): $\nu = 3306, 2913, 2861, 1429, 1355, 1237, 1030, 978, 696\text{ cm}^{-1}$. HRMS (APCI): calcd for $\text{C}_{16}\text{H}_{18}\text{NOS}$ $[\text{M} - \text{OH}]^+$ 272.1104; found 272.1107. $[\alpha]_{\text{D}}^{20} = +200$ (c 1, CH_2Cl_2).

(3*R*)-6,7-Bis(hydroxymethyl)-3,5-dimethyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**17b**). Obtained from compound **16b** (1.21 g, 4.50 mmol) as described in the general procedure. Purification by trituration with diethyl ether yields compound **17b** as a white solid (549 mg, 57%). mp 65–66 °C. ^1H NMR (400 MHz, CDCl_3): $\delta = 1.70$ (d, $J = 6.1$ Hz, 1H), 2.23 (s, 3H), 2.44 (bs, 2H), 3.92 (d, $J = 12.9$ Hz, 1H), 4.21 (d, $J = 12.9$ Hz, 1H), 4.48–4.55 (m, 4H), 5.33 (q, $J = 5.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 10.0, 25.7, 26.7, 56.3, 56.6, 58.1, 113.2, 122.0, 123.0, 130.6$. IR (ATR): $\nu = 3272, 2913, 2858, 1528, 1437, 1367, 1325, 1241, 971\text{ cm}^{-1}$. HRMS (EI): calcd for $\text{C}_{10}\text{H}_{15}\text{NO}_2\text{S}$ $[\text{M}]^+$ 213.0824; found 213.0828. $[\alpha]_{\text{D}}^{20} = +110$ (c 1, CH_2Cl_2).

(3*S*)-6,7-Bis(hydroxymethyl)-3,5-dimethyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole (**17c**). Obtained from compound **16c** (1.12 g, 4.17 mmol) as described in the general procedure. Purification by trituration with diethyl ether yields compound **17c** as a white solid (669 mg, 75%). mp 65–66 °C. ^1H NMR (400 MHz, CDCl_3): $\delta = 1.70$ (d, $J = 6.2$ Hz, 1H), 2.23 (s, 3H), 2.69 (bs, 2H), 3.91 (d, $J = 12.9$ Hz, 1H), 4.20 (d, $J = 12.9$ Hz, 1H), 4.46–4.52 (m, 4H), 5.33 (q, $J = 5.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 10.0, 25.7, 26.7, 56.3, 56.6, 58.1, 113.2, 122.0, 123.0, 130.6$. IR (KBr): $\nu = 3286, 2913, 2877, 1529, 1442, 1327, 985\text{ cm}^{-1}$. HRMS (APCI): calcd for $\text{C}_{10}\text{H}_{14}\text{NOS}$ $[\text{M} - \text{OH}]^+$ 196.0791; found 196.0791. $[\alpha]_{\text{D}}^{20} = -110$ (c 1, CH_2Cl_2).

Synthesis of hydroxymethyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-2,2-dioxides **14 and **15**.** The synthesis was performed based on a procedure described in the literature.¹⁹ A suspension of compound **13** (0.37 g, 1.03 mmol) and finely powdered NaBH_4 (16 equiv., 0.62 g, 16.48 mmol) in anhydrous THF (20 mL) was stirred for 20 min at 70 °C, followed by the dropwise addition of methanol (2.1 mL). The reaction mixture was left stirring for 24 h at 70 °C under nitrogen atmosphere. The reaction was cooled to room temperature, quenched by adding saturated aqueous NH_4Cl solution (3 mL) and stirred

for 1 h. The aqueous phase was extracted with ethyl acetate (3 × 20 mL), the organic extracts were dried (Na₂SO₄) and the solvent evaporated. Purification by column chromatography [hexane/EtOAc (1:3), hexane/EtOAc (1:5), then EtOAc] gave in order of elution methyl (3*R*)-7-hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6-carboxylate-2,2-dioxide (**14**) (107 mg, 31%) and (3*R*)-6,7-bis(hydroxymethyl)-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-2,2-dioxide (**15**) (166 mg, 53%).

Methyl (3*R*)-7-hydroxymethyl-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-6-carboxylate-2,2-dioxide (14**).** mp 112–114 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.27 (s, 3H), 3.87 (s, 3H), 4.22 (d, *J* = 15.2 Hz, 1H), 4.48 (d, *J* = 15.2 Hz, 1H), 4.61 (d, *J* = 13.2 Hz, 1H), 4.69 (d, *J* = 13.2 Hz, 1H), 5.91 (s, 1H), 7.02–7.04 (m, 2H), 7.41–7.47 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 12.6, 48.2, 51.5, 57.1, 77.8, 113.6, 118.9, 122.2, 126.8, 129.6, 130.62, 130.64, 135.7, 166.2. IR (KBr): ν = 3132, 1712, 1672, 1454, 1404, 1317, 1138 cm⁻¹. HRMS (EI): calcd for C₁₆H₁₇NO₅S [M]⁺ 335.0827; found 335.0827. [α]_D²⁰ = 0.0 (c 1, CH₂Cl₂).

(3*R*)-6,7-Bis(hydroxymethyl)-5-methyl-3-phenyl-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-2,2-dioxide (15**).** mp > 170 °C (with decomposition). ¹H NMR (400 MHz, CDCl₃): δ = 2.00 (s, 3H), 2.50 (bs, 1H), 2.77 (bs, 1H), 4.22 (d, *J* = 15.0 Hz, 1H), 4.43 (d, *J* = 15.0 Hz, 1H), 4.59–4.65 (m, 4H), 5.88 (s, 1H), 7.05–7.07 (m, 2H), 7.41–7.45 (m, 3H). ¹³C NMR (100 MHz, CDCl₃): δ = 10.1, 48.4, 55.8, 56.6, 78.2, 118.2, 119.2, 121.6, 126.2, 127.1, 129.4, 130.4, 131.3. IR (KBr): ν = 3532, 3454, 2981, 2923, 2873, 1311, 1130, 987, 700 cm⁻¹. HRMS (ESI): calcd for C₁₅H₁₇NO₄SNa [M + Na]⁺ 330.0771; found 330.0764. [α]_D²⁰ = +20.0 (c 0.25, CH₂Cl₂).

Biological evaluation

Human cell lines. Human colorectal adenocarcinoma HCT116 cell lines expressing p53 and its p53-null isogenic derivative (HCT116 p53^{-/-}) were provided by B. Vogelstein (The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA), triple-negative metastatic breast adenocarcinoma (MDA-MB-231), pancreatic ductal adenocarcinoma (PANC-1), and melanoma (A375) cell lines were purchased from ATCC (Rockville, MD, USA). HCT116 and A375 cell lines were cultured in monolayer in RPMI-1640 medium with 2 mM L-glutamine from Biowest (Biowest, VWR, Carnaxide, Portugal), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco, Alfacene, Lisboa, Portugal) and PANC-1 and MDA-MB-231, in DMEM high glucose (4.5 g L⁻¹ glucose) with L-glutamine and sodium pyruvate, supplemented with 10% heat-inactivated FBS, at 37 °C, 5% CO₂.

Sulforhodamine B (SRB) assay. 5 × 10³ cells per well were seeded in 96-well plates for 24 h and then treated with serial dilutions of the appropriate compound ranging from 0.2 to 50 μM and incubated for 48 h. IC₅₀ values for each cell line were determined by the sulforhodamine B (SRB) assay, as previously described.²⁰

Author contributions

MH, AMP, ABP, MS: chemical synthesis; CC, JR: cell biology studies; MS, LS, TPM: project conception and supervision; MS, LS, TPM: manuscript preparation.

Conflicts of interest

One patent application protecting the compounds disclosed in this manuscript has been filed by the following authors M. I. L. S., L. S., and T. M. V. D. P. M.

Acknowledgements

The authors thank Coimbra Chemistry Centre (CQC), supported by the Portuguese Agency for Scientific Research “Fundação para a Ciência e a Tecnologia” (FCT), through project UIDB/00313/2020 (<https://doi.org/10.54499/UIDB/00313/2020>) and UIDP/00313/2020 (<https://doi.org/10.54499/UIDP/00313/2020>), co-funded by COMPETE2020-UE. This research was also funded by FCT/MCTES, through LAQV/REQUIMTE (UIDP/QUI/50006/2020). M. I. L. S. (DL57/2016/CP1370/CT0041, <https://doi.org/10.54499/DL57/2016/CP1370/CT0041>), J. L. P. R. (PhD fellowship PD/BD/143160/2019 “MedChemTrain programme”) and C. S. C. C. (PhD fellowship 2021.06305.BD) thank FCT for financial support. The authors also acknowledge the UC-NMR facility for obtaining the NMR data (<https://www.uc.pt/uc-nmr/>).

References

- G. W. Prager, S. Braga, B. Bystricky, C. Qvortrup, C. Criscitiello, E. Esin, G. S. Sonke, G. A. Martínez, J. S. Frenel, M. Karamouzis, M. Strijbos, O. Yazici, P. Bossi, S. Banerjee, T. Troiani, A. Eniu, F. Ciardiello, J. Taberero, C. C. Zielinski, P. G. Casali, F. Cardoso, J. Y. Douillard, S. Jezdic, K. McGregor, G. Bricalli, M. Vyas and A. Ilbawi, *ESMO Open*, 2018, 3, e000285.
- WHO report on cancer: setting priorities, investing wisely and providing care for all*, World Health Organization, Geneva, 2020.
- H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, *Ca-Cancer J. Clin.*, 2021, 71, 209–249.
- E. Dekker, P. J. Tanis, J. L. A. Vleugels, P. M. Kasi and M. B. Wallace, *Lancet*, 2019, 394, 1467–1480.
- H. Ramos, M. I. L. Soares, J. Silva, L. Raimundo, J. Calheiros, C. Gomes, F. Reis, F. A. Monteiro, C. Nunes, S. Reis, B. Bosco, S. Piazza, L. Domingues, P. Chlapek, P. Vlcek, P. Fabian, A. T. Rajado, A. T. P. Carvalho, R. Veselska, A. Inga, T. M. V. D. Pinho e Melo and L. Saraiva, *Cell Rep.*, 2021, 35, 108982.
- T. M. V. D. Pinho e Melo, M. I. L. Soares, D. M. Barbosa, A. M. d'A. R. Gonsalves, A. M. Beja, J. A. Paixão, M. R. Silva and L. A. da Veiga, *Tetrahedron*, 2000, 56, 3419–3424.
- L. Szilágyi and Z. Györgydeák, *J. Am. Chem. Soc.*, 1979, 101, 427–432.
- Z. Györgydeák, M. Kajtár-Peredy, J. Kajtár and M. Kajtár, *Liebigs Ann. Chem.*, 1987, 927–934.

- 9 T. M. V. D. Pinho e Melo, C. S. B. Gomes, A. M. d'A. R. Gonsalves, J. A. Paixão, A. M. Beja, M. R. Silva and L. A. da Veiga, *Tetrahedron*, 2002, **58**, 5093–5102.
- 10 M. I. L. Soares, A. F. Brito, M. Laranjo, J. A. Paixão, M. F. Botelho and T. M. V. D. Pinho e Melo, *Eur. J. Med. Chem.*, 2013, **60**, 254–262.
- 11 M. I. L. Soares, A. F. Brito, M. Laranjo, A. M. Abrantes, M. F. Botelho, J. A. Paixão, A. M. Beja, M. R. Silva and T. M. V. D. Pinho e Melo, *Eur. J. Med. Chem.*, 2010, **45**, 4676–4681.
- 12 A. Regueiro-Ren, in *Applications of Heterocycles in the Design of Drugs and Agricultural Products*, ed. N. A. Meanwell and M. L. Lolli, 2021, vol. 134, pp. 1–30.
- 13 T. M. V. D. Pinho e Melo, M. I. L. Soares, A. M. D. R. Gonsalves and H. McNab, *Tetrahedron Lett.*, 2004, **45**, 3889–3893.
- 14 T. M. V. D. Pinho e Melo, M. I. L. Soares, A. M. d'A. R. Gonsalves, J. A. Paixão, A. M. Beja, M. R. Silva, L. A. da Veiga and J. C. Pessoa, *J. Org. Chem.*, 2002, **67**, 4045–4054.
- 15 T. M. V. D. Pinho e Melo, M. I. L. Soares, A. M. d'A. R. Gonsalves, J. A. Paixão, A. M. Beja and M. R. Silva, *J. Org. Chem.*, 2005, **70**, 6629–6638.
- 16 K. Santos, M. Laranjo, A. M. Abrantes, A. F. Brito, C. Goncalves, A. B. S. Ribeiro, M. F. Botelho, M. I. L. Soares, A. S. R. Oliveira and T. M. V. D. Pinho e Melo, *Eur. J. Med. Chem.*, 2014, **79**, 273–281.
- 17 S. Yang, T. N. Wang, Y. A. Zhou, L. Shi, A. D. Lu and Z. W. Wang, *Molecules*, 2021, **26**, 383.
- 18 I. R. Schmolka and P. E. Spoerri, *J. Org. Chem.*, 1957, **22**, 943–946.
- 19 N. Boechat, J. C. S. da Costa, J. D. Mendonça, P. S. M. de Oliveira and M. V. N. de Souza, *Tetrahedron Lett.*, 2004, **45**, 6021–6022.
- 20 L. Raimundo, A. Paterna, J. Calheiros, J. Ribeiro, D. S. P. Cardoso, I. Piga, S. J. Neto, D. Hegan, P. M. Glazer, S. Indraccolo, S. Mulhovo, J. L. Costa, M.-J. U. Ferreira and L. Saraiva, *Br. J. Pharmacol.*, 2021, **178**, 3627–3647.